Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume – What’s Next?

Pharming Group (NASDAQ:PHAR) saw unusually-high trading volume on Wednesday . Approximately 6,553 shares traded hands during trading, an increase of 35% from the previous session’s volume of 4,843 shares.The stock last traded at $8.72 and had previously closed at $8.20.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PHAR. Jefferies Financial Group initiated coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Tuesday, December 17th. Finally, Oppenheimer decreased their price target on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Stock Performance

The company has a market capitalization of $597.30 million, a PE ratio of -33.77 and a beta of -0.10. The firm has a 50-day moving average of $9.18 and a two-hundred day moving average of $8.43. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.